Systemic Anti-Cancer Therapy Regimen Library
Test dose (Neuroendocrine tumour Advanced - short-acting octreotide)
Treatment Overview
Test dose - Single dose, repeated on any 3 separate days.
Cycles 1 to 3 - 1 days
Cycle details
Cycles 1 to 3 - 1 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| octreotide | 500 microgram | subcutaneous injection | 1 |
Full details
Cycles 1 to 3 - 1 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| octreotide | 500 microgram | subcutaneous injection |
Instructions:
As a single dose, repeat on any 3 separate days. |
Supportive Care Factors
No supportive care factors specified
References
Max Health Ltd. Octreotide New Zealand Data Sheet 27 August 2021. https://www.medsafe.govt.nz/profs/datasheet/o/OctreotideinjMaxRXinj.pdf (Accessed 15 July 2025).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.